Sort

Search

01/01/2025 Peripheral precocious puberty in girls with McCune-Albright syndrome: a case series
Faria, AG, Montenegor, LR, Jorge, AAL, Martin, RM, Fragoso, MCBV, Tinano, FR, Seraphim, CE, Canton, APM, Gomes, LG, Martos-Moreno, GA, García, IT, Carcavilla, A, Tirado-Capistros, M, Souza-Pinto, NC, Argente, J, Latronico, AC, Mendonca, BB, Brito, VN. Peripheral precocious puberty in girls with McCune-Albright syndrome: a case series. Archives of Endocrinology Metabolism. 2025; 69(2)DOI:10.20945/2359-4292-2024-0459. PMID:40366083. IF:2.300(Q3/7D).
01/01/2025 Retinal Microperimetry as a Novel Tool for Early Detection of Subclinical Cognitive Dysfunction and Brain Damage in Type 1 Diabetes: A Pilot Study
Mateu-Salat, M, Stanton-Yonge, N, Santaló, FS, Vela, JI, Cascajosa, JD, Pérez, ES, Rego-Lorca, D, Chico, A. Retinal Microperimetry as a Novel Tool for Early Detection of Subclinical Cognitive Dysfunction and Brain Damage in Type 1 Diabetes: A Pilot Study. Endocrinology Diabetes & Metabolism. 2025; 8(1)DOI:10.1002/edm2.70018. PMID:39707866. IF:(Q/D).
01/01/2025 Acute unilateral conjunctivitis as first manifestation of monkeypox viral infection after the 2023 vaccination campaign
Saladrigas, A, Sabater-Cruz, N, Gil, MA, Lázaro-Rodríguez, V, Caminal-Caramés, M, Conversa, S, del Campo, Z. Acute unilateral conjunctivitis as first manifestation of monkeypox viral infection after the 2023 vaccination campaign. JOURNAL FRANCAIS D OPHTALMOLOGIE. 2025; 48(1)DOI:10.1016/j.jfo.2024.104318. PMID:39394006. IF:1.100(Q3/8D).
01/01/2025 Persistence, effectiveness, and tolerability of anti-calcitonin gene-related peptide monoclonal antibodies in patients with chronic migraine
de Dios, A, Pages-Puigdemont, N, Ojeda, S, Riera, P, Pelegrín, R, Morollon, N, Belvís, R, Real, J, Masip, M. Persistence, effectiveness, and tolerability of anti-calcitonin gene-related peptide monoclonal antibodies in patients with chronic migraine. HEADACHE. 2025; 65(1)DOI:10.1111/head.14827. PMID:39268992. IF:4.000(Q1/2D).
01/01/2025 Cyclosporine for the treatment of chronic spontaneous urticaria refractory to antihistamines and omalizumab: a case series
Mateu-Arrom, L, Giménez-Arnau, AM, Expósito-Serrano, V, Bonfill-Orti, M, Serra-Baldrich, E, Yélamos, O, Spertino, J. Cyclosporine for the treatment of chronic spontaneous urticaria refractory to antihistamines and omalizumab: a case series. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2025; 64(1)DOI:10.1111/ijd.17358. PMID:38940007. IF:3.200(Q1/3D).
01/01/2025 Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis
Cerezuela-Fuentes, P, Gonzalez-Cao, M, Puertolas, T, Manzano, JL, Maldonado, C, Yelamos, O, Berciano-Guerrero, MA, Martin-Liberal, J, Muñoz-Couselo, E, Espinosa, E, Drozdowskyj, A, Berrocal, A, Soria, A, Marquez-Rodas, I, Martin-Algarra, S, Quindos, M, Puig, S. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis. Clinical & Translational Oncology. 2025; 27(1)DOI:10.1007/s12094-024-03583-5. PMID:38951438. IF:2.500(Q3/6D).
01/01/2025 Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN-FRT expert consensus
Torres, T, Brembilla, NC, Langley, RG, Warren, RB, Thaci, D, Kolios, AGA, Prinz, JC, Londono-Garcia, A, Nast, A, Santin, M, Goletti, D, Abreu, M, Spuls, P, Boehncke, WH, Puig, L. Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN-FRT expert consensus. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2025; 39(1)DOI:10.1111/jdv.20287. PMID:39149807. IF:8.000(Q1/1D).
01/01/2025 Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology
Carmona-Rocha, E, Rusiñol, L, Puig, L. Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology. Pharmaceutics. 2025; 17(1)DOI:10.3390/pharmaceutics17010091. PMID:39861739. IF:5.500(Q1/1D).